Aurinia Pharmaceuticals I...

AI Score

0

Unlock

7.53
-0.24 (-3.09%)
At close: Jan 14, 2025, 3:59 PM
7.56
0.41%
After-hours Jan 14, 2025, 07:57 PM EST
undefined%
Bid 7.3
Market Cap 1.08B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.15
PE Ratio (ttm) -50.2
Forward PE n/a
Analyst Buy
Ask 10.17
Volume 1,418,710
Avg. Volume (20D) 1,385,139
Open 7.85
Previous Close 7.77
Day's Range 7.52 - 7.94
52-Week Range 4.71 - 10.67
Beta undefined

About AUPH

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada....

Industry Biotechnology
Sector Healthcare
IPO Date Sep 3, 2014
Employees 300
Stock Exchange NASDAQ
Ticker Symbol AUPH

Analyst Forecast

According to 3 analyst ratings, the average rating for AUPH stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 32.80% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Aurinia Pharmaceuticals Inc. is scheduled to release its earnings on Feb 13, 2025, before market opens.
Analysts project revenue of $59.94M, reflecting a 32.92% YoY growth and earnings per share of 0, making a -100.00% decrease YoY.
2 months ago · Source
+10.9%
Aurinia Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription
4 months ago · Source
+0.77%
Aurinia Pharmaceuticals shares are trading higher after the company announced a board restructuring consisting of seven members.